Ratio Therapeutics Inc. has closed a $50 million series B financing to expand application of its proprietary technology platforms, Trillium and Macropa, to develop novel best-in-class radiopharmaceuticals.
Cantharidin, a natural product coming from blister beetles, has anti-proliferative activity in several cancer cell lines such as leukemia, myeloma or colon cancer cells.
There is increasing interest in studying exosome molecules, and particularly long non-coding RNAs (lncRNAs), in the diagnosis of gastric cancer. Microarray analysis was performed from samples obtained from patients with gastric cancer who underwent endoscopic resection.
Researchers at ETH Zurich have identified a proteomic signature that could recognize long COVID six months after acute infection. Biologically, the signature indicated that the complement system remained active in patients with long COVID six months after infection. Translationally, it could lead to a diagnostic test for long COVID, and suggests that targeting the complement system could be a therapeutic approach to prevent or treat the disorder.
Mainline Biosciences (Shanghai) Co. Ltd. has described peptides acting as tachykinin NK1 receptor antagonists reported to be useful for the treatment of pain and opioid dependence.
Chulalongkorn University has divulged programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) modulators reported to be useful for the treatment of cancer.
Cincinnati Children’s Hospital Medical Center has identified IL-1 receptor-associated kinase (IRAK) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has synthesized molecular glue compounds targeting protein cereblon (CRBN) acting as CRBN/target protein interaction inducers reported to be useful for the treatment of cancer.
Researchers at University of Arizona and University of Dundee have disclosed dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes, osteoarthritis, Down syndrome, inflammatory disorder, autoimmune and Alzheimer’s disease.
RSS
